Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06232486

Relationship Between Serum Vitamin D Levels and Postherpetic Neuralgia.

1. The correlations of serum vitamin D level, serum calcium level and osteoporosis degree with disease severity, treatment response, incidence of Post-Herpes zoster(PHN) and disease prognosis in Herpes zoster(HZ) patients were studied. 2. To investigate the role of inflammation-related factors and immune-related factors in the occurrence and development of HZ mediated by low vitamin D level.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tongji Hospital

Wuhan, Hubei, 430030, China

About this study

Herpes zoster is a neuropathic disease which induce by the varicella-herpes virus reactivation.and postherpetic neuralgia (PHN) is the most common complication. Currently,the mechanism of herpes zoster still unclearly even though there had much study about it .Vitamin D is an essential vitamin for human body, which has the function of maintaining calcium and phosphorus homeostasis and immune regulation. Vitamin D is a natural antiviral substance, and vitamin D deficiency can affect the body's antiviral ability, thereby promoting varicella-zoster virus(VZV) reactivation, and may promote the development of PHN through continuous neuroinflammation. Therefore, vitamin D level may be related to the occurrence and progression of HZ. this study intends to use an observational cohort study design to investigate the correlation of serum vitamin D level and osteoporosis degree with the severity of the herpes zoster disease, Although we plan to further explore the role of inflammatory state in this process.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years.
  • The patient was diagnosed with herpetic neuralgia and the course of disease was ≤3 months.
  • Can cooperate with the completion of inquiry and scale evaluation.

Exclusion criteria

  • Severe spinal disease (fracture, malignancy, acute or chronic infection) confirmed by previous spinal surgery or imaging.
  • Previous history of head trauma.
  • Have autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, leucothrombocytopenia).
  • Suffering from mental disorders, intellectual disability, epilepsy and other diseases.
  • A history of substance abuse, drug abuse or alcohol abuse.
  • Pregnant or breastfeeding women.
  • And recent participation in other clinical studies.

Treatment and study plan

Primary outcomes

  1. Serum 25-hydroxyvitamin D levels

    Time frame: herpetic neuralgia <3 month

    Vitamin D deficiency: < 20 nmol/L. Vitamin D deficiency: 20-30 nmol/L. Normal vitamin D: > 30 nmol/L.

Secondary outcomes

  1. C-reactive protein

    Time frame: Day 2 in the hospital

    An according to early infection stricture in serum.When CRP>20mg/l is considered abnormally level .

  2. Lymphocytes

    Time frame: Day 2 in the hospital

    Lymphocytes is considered an label of virus infection when it outlier.

  3. Red blood cell distribution width,RDM(fl)

    Time frame: Day 2 in the hospital

    It is a reflects the inhomogeneity of red cell size.

  4. Red blood cell count,RBC

    Time frame: Day 2 in the hospital

    One of main recording to diagnosis of anemia . nomal mal (4-5.5)×10-12/L. nomal femal (3.5-5.0)×10-12/L.

  5. Mean red cell volum,MVC

    Time frame: Day 2 in the hospital

    It is a label of red cell size.normal range from 80 to 100fl.

  6. Creatinine

    Time frame: Day 2 in the hospital

    It is a metabolite of muscle and there are have many reasons induce creatinine rise,such as chronic or acute kidney damage,Medicine side effect.normal range:53-106umol/l.

  7. Albumin

    Time frame: Day 2 in the hospital

    It is a protein that is found in many animal tissues and serum.The normal range 35-50g/L.

  8. Alkaline phosphatase

    Time frame: Day 2 in the hospital

    Alkaline phosphatase (ALP or AKP) is an enzyme that is widely distributed in human liver, bone, intestine, kidney, placenta and other tissues and is excreted from the liver to the bile.normal male: 45~125U/L;normal female:20~49岁35~100U/L

  9. Uric acid

    Time frame: Day 2 in the hospital

    Uric acid is the end product of purine metabolism. It is a trioxa purine, and its alcohol form is weakly acidic.normal male:150~416μmol/L,normal female:89~357μmolL

  10. Blood glucose

    Time frame: Day 2 in the hospital

    The production and utilization of blood sugar in normal people are in a state of dynamic balance, maintaining a relatively stable level, which is because the source and route of blood sugar are roughly the same result.Fasting blood-glucose(FBG):4.4~6.1mmol/L。

  11. diastolic blood pressure,

    Time frame: Day 2 in the hospital

    An indicator in blood pressure measurement that indicates the pressure of the heart's arterial blood against the vessel walls during diastole. It is usually measured in millimeters of mercury (mmHg).

  12. systolic blood pressure

    Time frame: Day 2 in the hospital

    A type of blood pressure that refers to the pressure of blood against the artery walls when the heart contracts. It is often used as a measure of cardiovascular health(mmHg).

  13. total cholesterol

    Time frame: Day 2 in the hospital

    The sum of all cholesterol in the blood, including LDL cholesterol and HDL cholesterol. High levels of total cholesterol may increase the risk of cardiovascular disease.normal range:<5.18mmol/L(<200mg/dl)

  14. triglycerides

    Time frame: Day 2 in the hospital

    Triglyceride (TG) is a constituent of lipids, which is formed by glycerol and three fatty acids. normal range<1.70mmol/L.

  15. serum Ca2+ level

    Time frame: Day 2 in the hospital

    Ionic calcium refers to the concentration of calcium ions in the blood, also known as serum calcium. Normal levels of ionic calcium maintain a stable range in the blood, generally 2.1-2.6 mmol/L(or 8.5-10.5 mg/dL).

  16. Cellular immune indexes C3

    Time frame: Day 2 in the hospital

    Complement C3 can promote phagocytic cells to move to promote phagocytosis, promote B cell proliferation, and have a solubilization effect on soluble immune complex.

  17. Cellular immune indexes C4

    Time frame: Day 2 in the hospital

    Complement C4 is an important component of the classical activation pathway of complement, which is divided into C4a and C4b. The release of C4a can induce mast cells to release histamine, increase the permeability of blood vessels and cause local exudative inflammation. C4b mainly plays a role in mediating the complement cascade, promoting phagocytosis, participating in preventing the deposition of immune complexes, and neutralizing viruses.

  18. interleukin(IL)-10

    Time frame: Day 2 in the hospital

    Interleukin-10 is a multi-cellular, multifunctional cytokine that regulates cell growth and differentiation, participates in inflammatory and immune responses, and is a recognized inflammatory and immunosuppressive factor.

  19. interleukinIL-6

    Time frame: Day 2 in the hospital

    The target cells of IL-6 action are many, including macrophages, hepatocytes, quiescent T cells, activated B cells and plasma cells.

  20. interleukinIL-8

    Time frame: Day 2 in the hospital

    Interleukin-8, or IL-8 for short, is a cytokine in the family of chemokines. Its role in participating in and regulating the physiological and pathological processes of human reproduction has been confirmed, and one of its mechanisms is to bind to its specific receptors.

  21. tumor necrosis factor(TNF)-a

    Time frame: Day 2 in the hospital

    TNF-α, also known as cachexin and TNFSF1A, is an adipokine involved in systemic inflammation and is one of the cytokines that stimulate the acute phase response. TNF-α transmits information to the nucleus through specific receptors on the cell membrane, thus producing complex biological activities such as promoting cell proliferation and differentiation, immune regulation, inflammation mediation, and anti-tumor.

  22. Bone mineral density T value

    Time frame: Day 2 in the hospital

    Bone mineral density T value,present the bone density to predict osteoporosis.

  23. magnetic resonance imaging

    Time frame: Day 2 in the hospital

    Results of MRI examination,exclude tumor or infection

  24. cluster of differentiation 4(CD4)+

    Time frame: Day 2 in the hospital

    CD4 cells, refers to the surface of the CD4+T molecule T lymphocytes, is an important immune cell in the human immune system, because the HIV attack object is CD4+T cells, so its detection results on the AIDS treatment effect and the judgment of the patient's immune function has an important role.

  25. cluster of differentiation 8(CD8)+

    Time frame: Day 2 in the hospital

    CD8+T cells generally refer to cytotoxic T lymphocytes. Cytotoxic T lymphocytes (CTL), a subdivision of white blood cells, are specific T cells that secrete various cytokines to participate in immune function.

  26. numeric rating scale(NRS)

    Time frame: Day 2 in the hospital

    The NRS pain Score is an exponential scale that uses 0 to 10 to represent different levels of pain, 0 being painless and 10 being severe, and asks the patient how bad the pain is, or to circle a number that best represents their pain.

  27. numeric rating scale(NRS)

    Time frame: After the therapy in hospital

    The NRS pain Score is an exponential scale that uses 0 to 10 to represent different levels of pain, 0 being painless and 10 being severe, and asks the patient how bad the pain is, or to circle a number that best represents their pain.

  28. numeric rating scale(NRS)

    Time frame: After the therapy 1 month

    The NRS pain Score is an exponential scale that uses 0 to 10 to represent different levels of pain, 0 being painless and 10 being severe, and asks the patient how bad the pain is, or to circle a number that best represents their pain.

  29. numeric rating scale(NRS)

    Time frame: After the therapy 2 month

    The NRS pain Score is an exponential scale that uses 0 to 10 to represent different levels of pain, 0 being painless and 10 being severe, and asks the patient how bad the pain is, or to circle a number that best represents their pain.

  30. numeric rating scale(NRS)

    Time frame: After the therapy 3 month

    The NRS pain Score is an exponential scale that uses 0 to 10 to represent different levels of pain, 0 being painless and 10 being severe, and asks the patient how bad the pain is, or to circle a number that best represents their pain.

  31. DN4

    Time frame: Day 2 in the hospital

    A table of pain assesment that mainly about neuropathic pain.

  32. DN4

    Time frame: After therapy in hospital

    A table of pain assesment that mainly about neuropathic pain.

  33. DN4

    Time frame: After therapy 1 month

    A table of pain assesment that mainly about neuropathic pain.

  34. DN4

    Time frame: After therapy 2 month

    A table of pain assesment that mainly about neuropathic pain.

  35. DN4

    Time frame: After therapy 3 month

    A table of pain assesment that mainly about neuropathic pain.

Sponsors and collaborators

Lead sponsor

Feng Gao

Other

Registry information

Official study title

Association Between Serum Vitamin D and Postherpetic Neuralgia, A Prospective Observation Study.

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Jan 30, 2024
Registry last updated
Jan 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.